Faculty Collaboration Database

1. Kilari D, Mohile SG. Management of cancer in the older adult. Clin Geriatr Med. 2012 Feb;28(1):33-49.

2. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An observational study of plasma vascular endothelial growth factors (VEGF) A and D expression in non-localized prostate cancer. J Mens Health. 2012 Sep 01;9(3):182-189. PMCID: PMC3886726

3. Kilari D, Venci N, Friedberg J, Bennett JM. Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia. Leuk Res Rep. 2013;2(1):4-6. PMCID: PMC3850386

4. Kilari D, Dale W, Mohile SG. How we treat early systemic prostate cancer in older men. J Geriatr Oncol. 2014 Oct 01;5(4):337-42.

5. Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer. 2014 Jul;85(1):88-93. PMCID: PMC4090351

6. Xia S, Kohli M, Du M, Dittmar RL, Lee A, Nandy D, Yuan T, Guo Y, Wang Y, Tschannen MR, Worthey E, Jacob H, See W, Kilari D, Wang X, Hovey RL, Huang CC, Wang L. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget. 2015 Jun 30;6(18):16411-21. PMCID: PMC4599278

7. Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Oncotarget. 2017 Jan 10;8(2):3724-3745. PMCID: PMC5356914

8. Thompson JR, Zhu J, Kilari D, Wang L. Applications of Extracellular RNAs in Oncology. Mol Diagn Ther. 2017 Feb;21(1):1-11.

9. Flynn T, Guancial EA, Kilari M, Kilari D. Case Report: Spironolactone Withdrawal Associated With a Dramatic Response in a Patient With Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Feb;15(1):e95-e97.

10. Kilari D, Guancial E, Kim ES. Role of copper transporters in platinum resistance. World J Clin Oncol. 2016 Feb 10;7(1):106-13. PMCID: PMC4734932

11. Abbott DW, Kilari D, Senebouttarath K, Iczkowski KA. Squamous cell carcinoma of the prostate with concomitant adenocarcinoma in the absence of prior androgen deprivation therapy Case Reports in Clinical Pathology. 2016 June 01;3(2):60-63

12. Kilari D, Soto-Perez-de-Celis E, Mohile SG, Alibhai SM, Presley CJ, Wildes TM, Klepin HD, Demark-Wahnefried W, Jatoi A, Harrison R, Won E, Mustian KM. Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting. J Geriatr Oncol. 2016 Jul;7(4):293-304. PMCID: PMC4969104

13. Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, Kim ES. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. PLoS One. 2016;11(5):e0155503. PMCID: PMC4871463

14. Presley CJ, Dotan E, Soto-Perez-de-Celis E, Jatoi A, Mohile SG, Won E, Alibhai S, Kilari D, Harrison R, Klepin HD, Wildes TM, Mustian K, Demark-Wahnefried W. Gaps in nutritional research among older adults with cancer. J Geriatr Oncol. 2016 Jul;7(4):281-92. PMCID: PMC4969118

15. Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. Anticancer Res. 2016 Feb;36(2):495-501.

16. Raychaudhuri R, Riese MJ, Bylow K, Burfeind J, Mackinnon AC, Tolat PP, Iczkowski KA, Kilari D. Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. Clin Genitourin Cancer. 2017 Oct;15(5):e897-e901.

17. Du M, Giridhar KV, Tian Y, Tschannen MR, Zhu J, Huang CC, Kilari D, Kohli M, Wang L. Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. Oncotarget. 2017 Sep 08;8(38):63703-63714. PMCID: PMC5609954

18. Kapke J, Shaheen Z, Kilari D, Knudson P, Wong S. Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. Case Rep Oncol. 2017;10(3):897-909. PMCID: PMC5731100

19. Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2018 Sep;21(3):411-418. PMCID: PMC6126974

1. Kilari D, Carmel R, Dosik, H, Bellevue. Priapism: the first manifestation of Sickle cell trait. Poster presentation at the Society of General Internal Medicine (SGIM) annual meeting, 2008 May 01;Pittsburgh, PA.

2. Kilari D, Chakraborty S, Politsmakher A, Carmel R, Dosik, Hassan, S. Use of Advanced Care Directives by Ambulatory Chemotherapy Patients with various malignancies. Poster presentation at the New York Methodist Hospital (NYMH) Annual Research Retreat, 2009, New York, NY.

3. Kilari D, Carmel R, Gerecitano J. Methotrexate-related Lymphoproliferative disorders. Poster Presentation at the New York Chapter of American College of Physicians (NYACP) Annual Meeting 2009; New York, NY

4. Haque M, Kilari D, Bellevue R, Dosik H. Chronic Myeloid leukemia (CML) in a patient with sickle cell disease, Poster Presentation at the New York Methodist Hospital Resident Research day: Annual meeting, 2010 New York, NY.

5. Ninan N, Wentowski C, Sudore P, Abdelwahed A, Kilari D, Bellevue R, George L, MD. The Association Between Lipid Levels and Pulmonary Hypertension in Patients With Sickle Cell Disease. Poster presented at the American College of Chest Physicians (ACCP), Annual Meeting, 2010, Vancouver, British Columbia.

6. Kilari D, Pandya C, Fung C, Sahasrabudhe D, Brasacchio RA, Messing EM, Sievert L, Gupta SM; Characteristics and Outcomes of the elderly patients treated with peripheral androgen blockade. Poster presented at the Genitourinary American Society of Clinical Oncology (GU- ASCO), Annual Meeting, 2013, Orlando, Florida. J Clinical Oncology 31, 2013 (suppl 6; abstract 226)

7. Kilari D, Yao J, Scosyrev E, Evans EE, Sahasrabudhe DM; C35 a new prognostic tool and potential therapeutic target in patients with Prostate cancer. Poster presented at the Genitourinary American Society of Clinical Oncology (GU- ASCO), Annual Meeting, 2013, Orlando, Florida. J Clinical Oncology 31, 2013 (suppl 6; abstract 212)

8. Kilari D, Pandya C, Fung C, Sahasrabudhe D, Brasacchio RA, Messing EM, Sievert L, Gupta SM; The role of Comprehensive Geriatric Assessment (CGA) in identifying Elderly patients with Systemic Prostate Cancer (PCa) for Peripheral Androgen Blockade (PAB). Poster presented at the American Geriatric Society, annual meeting 2013. Grapevine, Texas.

9. Kilari D, Tang X, Chow C, Fujimoto J, Kalhor N, Swisher S, Wistuba I, Stewart DJ, Siddik ZH, Kim ES, Copper transporter expression (CTR1) and tissue platinum concentration in Non-small cell lung cancer. Poster Presented at the American Society of Clinical Oncology (ASCO), Annual Meeting, 2013, Chicago, IL. J Clinical Oncology 31, 2013 (suppl; abstract 2601)

10. Guancial E, Kilari D, Messing EM, Kim ES; Platinum concentration in bladder tissue treated with neoadjuvant chemotherapy and pathologic response. Poster Presented at the Genitourinary American Society of Clinical Oncology (GU- ASCO), Annual Meeting, 2015, San Francisco, CA. J Clinical Oncology 33, 2015 (suppl 7; abstract 341)

11. Kilari D, Iczkowski KA, Robin A, Pandya C, Messing EM, Guancial EA, Kim ES. Association between Copper Transporter Receptor 1(CTR1) Expression and Pathologic Outcomes in Platinum (Pt)-treated Bladder Cancer (BC) patients. Presented at the European Cancer Congress, annual meeting 2015, Vienna Austria.

12. Kilari D, Guancial E, Sahasrabudhe D, Bylow D, Burfeind J, Musto K, Feng C, Messing E, Mohile SG, Fung C.A Phase II Study of Enzalutamide (Enz) with Dutasteride (Dut) or Finasteride (Fin) in Men ≥ 65 Years with Hormone-naive Systemic Prostate Cancer (HNSPCa). Poster at GU ASCO, Feb 2017, Orlando, FL.

13. S Ramalingam, A Szabo, D Kilari, C Bhosekar, J Karpinski, SWong; Mannitol Enhances Cumulative Cisplatin Dose by Protecting against Cisplatin-Induced Nephrotoxicity Poster at ASCO 2017.

14. J. F. Borkenhagen, D. Eastwood, D. Kilari, W. A. See, J. D. Van Wickle, C. A. Lawton, W. A. Hall Prognostic Value of Clinical Stage T2 Substages in Prostate Cancer: A National Cancer Database Review. Poster at ASTRO 2017.

15. W. A. Hall, D Eastwood, D Kilari, J Wickle, R Raychaudhuri, J Borkenhagen, W See, C Lawton Androgen Deprivation Therapy (ADT) and Radiation Therapy (RT) Alone As Compared with Trimodality Therapy With ADT, RT, and Surgery In Men With High Risk, Non-Metastatic Adenocarcinoma Of The Prostate: Oral presentation at ASTRO 2017.

16. D Kilari, E Guancial2, D Sahasrabudhe, S Mohile, C Fung. Phase II Study of Enzalutamide (Enz) with Dutasteride (Dut) or Finasteride (Fin) in Men ≥ 65 Years with Hormone-naive Systemic Prostate Cancer (HNSPCa): Updated analysis: Poster at ESMO Madrid, Spain 2017.

17. A. Singavi, S. Menon, D. Kilari, A. Alqwasmi, P.S. Ritch, J.P. Thomas, A.L. Martin, C. Oxencis, S. Ali, B. George. Predictive biomarkers for Hyper-progression (HP) in response to Immune Checkpoint Inhibitors (ICI) – Analysis of Somatic Alterations (SAs) Poster at ESMO Madrid, Spain 2017.

18. D Kilari, P Hari, M Qayed, R Fraser, O Davila, S Kumar, TM Mark, Y Nieto, A D'Souza; Tandem high dose chemotherapy and autologous hematopoietic stem cell transplantation (SCT) is superior to single SCT for relapsed/refractory germ cell tumors (GCT). Poster at GU ASCO Feb 2018, San Francisco, California.

19. D. Petrylak, D. Smith, T.W. Flaig, J. Zhang, S.S. Sridhar, J. Ruether, E. Plimack, J. Merchan, D. Quinn, D. Kilari, S. Srinivas, J. Baranda, J. Lang, M. Milowsky, M. Galsky, A. Spira, E. Gartner, C. Wu, A. Melhem-Bertrandt, J.E. RosenbergEnfortumab Vedotin in Patients with Metastatic Urothelial Carcinoma with Prior Checkpoint Inhibitor Failure: A Prospective Cohort of an Ongoing Phase 1 Study. Poster at GU ASCO Feb 2018, San Francisco, California.

20. R Raychaudhuri, K Bylow, W Lea, T Zellmer, K Musto, J Burfeind, M Riese, D Kilari Liver-Directed Therapy (LDT) for Metastatic Renal Cell Carcinoma (mRCC): Single center experience. Poster at GU ASCO Feb 2018, San Francisco, California.

21. K. Bylow, D Kilari, M Riese, J Burfeind, M Stolley, R Prost, K Musto, R Neilson, A Szabo, J Thomas, AV. Ng, Effect of β-hydroxy-β-methyl butyrate (HMB) on muscle strength in older men with prostate cancer (PCA) started on androgen deprivation therapy (ADT): Preliminary results of an open-label, randomized trial. Poster, GU ASCO Feb 2018 San Francisco, California.

22. Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biol Blood Marrow Transplant. 2019 Jun;25(6):1099-1106. PMCID: PMC6559839

23. Robbins JR, Kilari D, Johnston F. Palliative care education for oncologists: how are we doing? Ann Palliat Med. 2019 Sep;8(4):364-371.

24. Borkenhagen JF, Eastwood D, Kilari D, See WA, Van Wickle JD, Lawton CA, Hall WA. Digital Rectal Examination Remains a Key Prognostic Tool for Prostate Cancer: A National Cancer Database Review. J Natl Compr Canc Netw. 2019 Jul 01;17(7):829-837.

25. Verdoorn BP, Feng C, Ricke WA, Sahasrabudhe DM, Kilari D, Kohli M. An observational study of plasma vascular endothelial growth factors (vegf) a and d expression in non-localized prostate cancer Journal of Men's Health. September 2012;9(3):182-189.

26. Udhane V, Maranto C, Hoang DT, Gu L, Erickson A, Devi S, Talati PG, Banerjee A, Iczkowski KA, Jacobsohn K, See WA, Mirtti T, Kilari D, Nevalainen MT. Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. Mol Cancer Ther. 2020 Jan;19(1):231-246. PMCID: PMC6946850

27. Lemke E, Sahasrabudhe D, Guancial E, Bylow K, Johnson S, Messing E, Kilari D. The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020? Clin Genitourin Cancer. 2020 Aug;18(4):e478-e483.

28. Du M, Tian Y, Tan W, Wang L, Wang L, Kilari D, Huang CC, Wang L, Kohli M. Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020 Dec;23(4):705-713. PMCID: PMC7501185

29. George G, Schmidt L, Tolat P, Riese M, Kilari D. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma. J Immunother Cancer. 2020 Feb;8(1). PMCID: PMC7057424

30. Kmak JA, Agarwal N, He Y, Heilmann AM, Miller VA, Ross JS, Pal SK, Ali SM, Kilari D. Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. Case Rep Oncol. 2020;13(1):456-461. PMCID: PMC7204854

31. Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A. CDK12-mutated prostate cancer: Clinical outcomes with standard therapies and immune checkpoint blockade JCO Precision Oncology. 2019;3:382-392.

32. Pierro M, Raychaudhuri R, Lea WB, Rilling W, Davis N, Bylow K, Kilari D. Outcomes With Liver-Directed Therapy for Genitourinary Malignancies: Single-Institution Experience. Clin Genitourin Cancer. 2021 Feb;19(1):87-91.

33. Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A. <i>CDK12</i>-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. JCO Precis Oncol. 2020;4:382-392. PMCID: PMC7363399

34. Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort Frontiers in Oncology. 22 October 2020;10.

35. Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Front Oncol. 2020;10:581189. PMCID: PMC7642690

36. Hall WA, Bedi M, Kilari D, Bylow KA, Burfeind J, Johnstone C, Siker M, Currey A, See WA, Nelson A, Johnson S, Straza M, Lawton CAF. Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial. Pract Radiat Oncol. 2021;11(6):527-533. PMCID: PMC8638529

37. Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):388-396. PMCID: PMC9385488

38. Beinhoff P, Sabharwal L, Udhane V, Maranto C, LaViolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT. Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development? Cancers (Basel). 2021 Oct 17;13(20). PMCID: PMC8533841

39. Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2022 Mar 15;128(6):1194-1205.

40. Huang J, Du M, Soupir A, Wang L, Tan W, Kalari KR, Kilari D, Park J, Huang CC, Kohli M, Wang L. Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2022 Sep 28;14(19). PMCID: PMC9562906

41. Mehra N, Fizazi K, de Bono JS, Barthélémy P, Dorff T, Stirling A, Machiels JP, Bimbatti D, Kilari D, Dumez H, Buttigliero C, van Oort IM, Castro E, Chen HC, Di Santo N, DeAnnuntis L, Healy CG, Scagliotti GV. Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. Oncologist. 2022 Oct 01;27(10):e783-e795. PMCID: PMC9526483

42. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B, ARASENS Trial Investigators. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022 Mar 24;386(12):1132-1142. PMCID: PMC9844551

43. Shayeb AM, McManus HD, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan CL, Barata P, Bilen MA, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan MD, McGregor B, Choueiri TK, McKay RR. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. Clin Genitourin Cancer. 2023 Feb;21(1):55-62.

44. Stevens-Haas C, Maniar V, Dietrich P, Langenstroer P, Joyce L, White S, Kilari D, Hong J, Johnson S. Management of Acute Liver Dysfunction Due to Budd-Chiari Syndrome in the Setting of Tumor Thrombus and Advanced Renal Cell Carcinoma. Urology. 2023 Mar;173:32-33.

45. Gallan AJ, Bhasin-Chhabra B, Kilari D, Johnson S, D'Souza A. Bystander LECT2 amyloidosis in tumor nephrectomy. CEN Case Rep. 2023 Feb;12(1):104-109. PMCID: PMC9892383

46. Pierro MJ, Kilari D. The Confusion Surrounding Androgen Deprivation Therapy and Cognitive Dysfunction. Eur Urol Focus. 2023 May;9(3):409-410.

47. Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y. Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. J Immunother Cancer. 2023 Feb;11(2). PMCID: PMC9950974

48. Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B. Comprehensive genomic profiling: Does timing matter? Frontiers in Oncology. 2023;13.

49. Hakimi K, Saidian A, Panian J, Barata P, Berg S, Chang SL, Saliby RM, Dzimitrowicz H, Emamekhoo H, Gross E, Kilari D, Lam E, Nguyen M, Meagher M, Wang L, Rauterkus GP, D'Andrea V, Yim K, Psutka S, Thapa B, Weise N, Zhang T, McKay RR, Derweesh IH. Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis. Clin Genitourin Cancer. 2023 Dec;21(6):694-702.

50. Panian J, Saidian A, Hakimi K, Ajmera A, Anderson WJ, Barata P, Berg S, Signoretti S, Lee Chang S, D'Andrea V, George D, Dzimitrowicz H, El Zarif T, Emamekhoo H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus GP, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay RR. Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. Oncologist. 2024 Oct 03;29(10):870-877. PMCID: PMC11448883

51. Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B. Comprehensive genomic profiling: Does timing matter? Front Oncol. 2023;13:1025367. PMCID: PMC9971445

52. Hwang C, Henderson NC, Chu SC, Holland B, Cackowski FC, Pilling A, Jang A, Rothstein S, Labriola M, Park JJ, Ghose A, Bilen MA, Mustafa S, Kilari D, Pierro MJ, Thapa B, Tripathi A, Garje R, Ravindra A, Koshkin VS, Hernandez E, Schweizer MT, Armstrong AJ, McKay RR, Dorff TB, Alva AS, Barata PC. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2023 Sep 05;6(9):e2334208. PMCID: PMC10507489

53. Dorff T, Zengin Z, Henderson N, Ali A, Nguyen C, Hwang C, Barata PC, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A. Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration. Res Sq. 2023 Aug 10. PMCID: PMC10441451

54. Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalanen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L. 5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapies. medRxiv. 2024 Oct 17. PMCID: PMC10615016

55. Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ, EORTC-55994 Study Group. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01;42(10):1114-1123. PMCID: PMC11637124

56. Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations. JCO Precis Oncol. 2024 Apr;8:e2300567. PMCID: PMC11018169

57. Zengin ZB, Henderson NC, Park JJ, Ali A, Nguyen C, Hwang C, Barata PC, Bilen MA, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin VS, Patel VG, Schweizer MT, Armstrong AJ, McKay RR, Alva A, Dorff T. Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate Cancer Prostatic Dis. 2025 Jun;28(2):378-384. PMCID: PMC12106060

58. Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, Kilari D, Thapa B, Piero M, Graham L, Tripathi A, Garje R, Koshkin VS, Hernandez E, Dorff TB, Schweizer MT, Alva AS, McKay RR, Armstrong AJ. Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2025 Jun;28(2):419-426. PMCID: PMC11739431

59. Thapa B, Nelson A, Kilari D. Novel targets in development for advanced renal cell carcinoma Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma. 1 November 2023:309-342.

60. Obasi J, Sharma K, De Sarkar N, Antonarakis ES, Kilari D. Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer Clinical Genitourinary Cancer. December 2024;22(6).

61. Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT. DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes. JCO Precis Oncol. 2024 Aug;8:e2400014. PMCID: PMC11346579

62. Thapa B, De Sarkar N, Giri S, Sharma K, Kim M, Kilari D. Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends. Cancer Manag Res. 2024;16:1267-1283. PMCID: PMC11416116

63. Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Ferrario C, Uemura H, Jones RJ, Fukasawa S, Peer A, Niu C, Poehlein CH, Qiu P, Suttner L, de Wit R, Schloss C, de Bono JS, Antonarakis ES. Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study. Prostate Cancer Prostatic Dis. 2025 Jun;28(2):411-418.

64. Davis NB, Kilari D, Kessler ER, Smelser WW. Editorial: Bladder preservation options for bladder cancer Frontiers in Oncology. 2024;14.

65. Pierro MJ, Gallan A, Kilari D. Non-clear cell renal cell carcinoma narrative review: where we are in 2024 Translational Cancer Research. 30 November 2024;13(11):6403-6412.

66. Patel MS, Almubarak M, Matta J, Ortiz-Sanchez C, Encarnacion J, Ruiz-Deya G, Dutil J, Dhillon J, Yamoah K, Berglund A, Park H, Kilari D, Balagurunathan Y, Wang L, Park JY. 5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer. medRxiv. 2024 Oct 27. PMCID: PMC11537326

67. Davis NB, Kilari D, Kessler ER, Smelser WW. Editorial: Bladder preservation options for bladder cancer. Front Oncol. 2024;14:1493854. PMCID: PMC11464248

68. Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüroğlu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS, NIAGARA Investigators. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. 2024 Nov 14;391(19):1773-1786.

69. Obasi J, Sharma K, De Sarkar N, Antonarakis ES, Kilari D. Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2024 Dec;22(6):102187.

70. Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalainen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L. 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies. Commun Med (Lond). 2025 Mar 04;5(1):61. PMCID: PMC11880319

71. Bo AY, Cheng YC, George B, Kilari D, Thompson JR, Jorns JM. Online Portal Use of Pathology Reports in Patients With Solid Tumors. Arch Pathol Lab Med. 2025 Aug 01;149(8):734-740.

72. Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. Eur Urol Oncol. 2025 Apr;8(2):258-262.

73. Pierro MJ, Gallan A, Kilari D. Non-clear cell renal cell carcinoma narrative review: where we are in 2024. Transl Cancer Res. 2024 Nov 30;13(11):6403-6412. PMCID: PMC11651800

74. Basu A, Sidhom F, Hwang C, Ferguson J, Peyton C, Bae S, Kilari D, Desai A, Rais-Bahrami S. YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study. J Natl Compr Canc Netw. 2025 Mar 28;23(3.5).

75. Raychaudhuri R, Tuchayi AM, Low SK, Arafa AT, Graham LS, Gulati R, Pritchard CC, Montgomery RB, Haffner MC, Nelson PS, Yu EY, Hawley JE, Cheng HH, Mo G, Chen DL, Antonarakis ES, Kilari D, Hope TA, Iravani A, Schweizer MT. Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after ¹⁷⁷Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes. Eur Urol Oncol. 2025 Feb 06. PMCID: PMC12325686

76. Patel MS, Almubarak M, Matta J, Ortiz-Sanchez C, Encarnacion J, Ruiz-Deya G, Dutil J, Dhillon J, Yamoah K, Berglund A, Park H, Kilari D, Balagurunathan Y, Wang L, Park JY. 5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer. Front Oncol. 2025;15:1541878. PMCID: PMC12011585

77. Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study. Cancer Med. 2025 Oct;14(19):e71284. PMCID: PMC12486332

78. Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding CC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, Shin D, Pywell C, Basu A, Bilen MA, Zakharia Y, Barata P, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Davis NB, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. Eur Urol. 2025 Sep 14.

79. Zhong J, Jang A, Abuqayas B, Basu A, Benjamin DJ, Bhatlapenumarthi V, Bilen MA, Buch D, Chang M, Chin E, Darabi S, Dhanikonda N, Ghatalia P, Grigg CM, Grier AL, Jindal T, Jung J, Kilari D, Kumar HLS, Lee S, Neelands B, Pandya C, Pawalek J, Staggers J, Yildirim A, Zakharia Y, Zarrabi KK, Zimmerman M, Sledge G, Spetzler D, Elliott A, McKay RR, Barata PC. REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens. Oncologist. 2025 Jun 04;30(6). PMCID: PMC12204391

80. McKay RR, Nazari SS, Elliott A, Ribeiro JR, Rose BS, Barata PC, Kilari D, Garje R, Agarwal N, Smith N, Antonarakis ES, Bagrodia A, Beltran H. Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer. Oncologist. 2025 Nov 11;30(11). PMCID: PMC12609168

81. Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O. Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study. Oncologist. 2025 Nov 11;30(11). PMCID: PMC12605803

82. Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell C, Evans ST, Shin D, Bilen MA, Basu A, Kilari D, Tripathi A, Brown J, Emamekhoo H, Davis NB, Shah S, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study. Urol Oncol. 2026 Jan;44(1):65.e1-65.e11.

83. Panian J, Henderson NC, Herchenhorn D, Barata PC, Bilen MA, Graham L, Heath E, Hwang C, Supernois A, Kilari D, Thapa B, Koshkin VS, Jindal T, Nauseef JT, Sokolova A, Amery T, Zakharia Y, Schweizer MT, Raychaudhuri R, Reichert ZR, Dorff T, Armstrong AJ, Wang J, Alva A, McKay RR. Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617. Oncologist. 2025 Nov 11;30(11). PMCID: PMC12622373

84. Panian J, Henderson N, Barata PC, Bilen MA, Graham L, Heath EI, Herchenhorn D, Hwang C, Kilari D, Koshkin VS, Nauseef JT, Sokolova A, Zakharia Y, Schweizer MT, Dorff TB, Armstrong AJ, Alva AS, McKay RR. Association of tumor genetics with outcomes in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617. Journal of Clinical Oncology. June 2024;42(16):5050-5050.

85. Aggen DH, Garcia A, Saro Suarez JM, Sauer A, Cristiani S, Brophy FE, Streets S, Norry E, Nelson AA, Kilari D, Garmezy B, Charlson JA, Zugazagoitia J, Calvo E, Moreno I, Moreno V, Hoimes CJ, Hong DS, Cervantes A. New phase 1 SURPASS trial cohort: Early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma. Journal of Clinical Oncology. February 2024;42:TPS708-TPS708.

86. Nizam A, Jindal T, Jiang CY, Alhalabi O, Bakaloudi DR, Talukder R, Davidsohn MP, Nguyen CB, Oh E, Taylor AK, Lemke E, Kilari D, Hoimes CJ, Emamekhoo H, Gupta S, Bellmunt J, Grivas P, Campbell MT, Alva AS, Koshkin VS. Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study. Journal of Clinical Oncology. February 2024;42:537-537.

87. Bhatlapenumarthi V, De Sarkar N, Patwari A, Antonarakis ES, Nelson AA, Kilari D. Homologous recombination repair (HRR) alterations may be passenger events in patients with advanced prostate cancer (PC) with high tumor mutational burden (hTMB). Journal of Clinical Oncology. 2024;42(4):206-206.

88. Kilari D, Kadambi SG, Baran AM, Zittel J, Burfeind JD, Messing EM, Van Veldhuizen PJ, Bylow KA, Sahasrabudhe DM, Mohile SG, Fung C. A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC). Journal of Clinical Oncology. 2024;42(16_suppl):5089-5089.

89. McKay RR, Nazari S, Elliott A, Rose BS, Barata PC, Kilari D, Garje R, Agarwal N, Nabhan C, Beltran H, Antonarakis ES, Bagrodia A. Molecular and clinical correlates of high PSMA/FOLH1 mRNA expression in primary and metastatic prostate cancer (PC) Journal of Clinical Oncology. 2024;42(16).

90. Vaishampayan UN, Sweis RF, Kilari D, Tarhini AA, Gainor JF, Barve MA, Sonpavde GP, McKean M, Park DJ, Babu S, Ju Y, Liu L, Henry S, Gan L, Yap TA. Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part. Journal of Clinical Oncology. 2024;42(16):2507-2507.

91. Harrison MR, Bhavsar NA, Ged Y, Alva AS, Zakharia Y, Wong RL, Costello BA, Maughan BL, Kilari D, Jabusch S, Ward KT, Wulff-Burchfield EM, Zhang T, Page C, Troy JD, Scales CD, George DJ. Preliminary analysis of baseline characteristics, patient reported outcomes (PROs), and treatment selection in ODYSSEY Journal of Clinical Oncology. 2024;42(4).

92. Yamamoto KL, Henderson N, Hwang C, Barata PC, Bilen MA, Kilari D, Graham L, Garje R, Rothstein S, Koshkin VS, Tripathi A, Cackowski FC, Nauseef JT, Schweizer MT, Armstrong AJ, Dorff TB, Alva AS, McKay RR. The impact of SPOP gene alterations in men with metastatic prostate cancer: Results from the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium Journal of Clinical Oncology. 2024;42(4).

93. Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Nizam A, Basu A, Bilen MA, Zakharia Y, Milowsky MI, Brown JR, Kilari D, Emamekhoo H, Hoimes CJ, Khaki AR, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study. Journal of Clinical Oncology. 2024;42(4):652-652.

94. Jindal T, Alhalabi O, Nguyen CB, Bakaloudi DR, Nizam A, Bilen MA, Basu A, Zakharia Y, Milowsky MI, Brown JR, Kilari D, Shah S, Emamekhoo H, Grivas P, Hoimes CJ, Gupta S, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study Journal of Clinical Oncology. 2024;42(4).

95. Jiang CY, Hwang H, Jindal T, Qiao W, Epstein I, Nguyen CB, Gupta S, Shah S, Bilen MA, Milowsky MI, Hoimes CJ, Kilari D, Zakharia Y, Emamekhoo H, Grivas P, Bellmunt J, Alva AS, Koshkin VS, Campbell MT, Alhalabi O. Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database Journal of Clinical Oncology. 2024;42(4).

96. Nizam A, Jindal T, Jiang CY, Alhalabi O, Davidsohn MP, Bakaloudi DR, Talukder R, Nguyen CB, Oh E, Taylor AK, Bilen MA, Basu A, Kilari D, Emamekhoo H, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Outcomes with sacituzumab govitecan (SG) in patients (pts) with advanced urothelial carcinoma (aUC) and variant histologies (VH): Analysis of the UNITE study. Journal of Clinical Oncology. 2024;42(4_suppl):667-667.